DGX vs SYRE
Quest Diagnostics vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
DGX
Quest Diagnostics
69
Buy
VS
SYRE
Spyre Therapeutics, Inc.
70
Buy
| Metric | DGX | SYRE |
|---|
| AI Score |
69
|
70
|
| Price |
$234.30
|
$103.56
|
| P/E Ratio |
24.57×
|
-53.14×
|
| ROE |
13.8%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
33.1%
|
0.0%
|
| Debt / Equity |
0.85×
|
0.00×
|
| Dividend Yield |
1.4%
|
0.0%
|
| RSI (14) |
54.8
|
54.6
|
| Beta |
0.557
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for DGX versus SYRE.
SYRE leads by 1 points.
SYRE scores 70/100 (Buy) versus DGX at 69/100 (Buy).
DGX Committee View
80% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is bollinger bandwidth of 17.6% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 17.6% signals elevated volatility — Risk
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical